700 related articles for article (PubMed ID: 15569201)
21. Factors affecting genetic testing and decisions about prophylactic surgery.
Mahon SM
Clin J Oncol Nurs; 2001; 5(3):117-20. PubMed ID: 11899370
[TBL] [Abstract][Full Text] [Related]
22. The development of interval breast malignancies in patients with BRCA mutations.
Komenaka IK; Ditkoff BA; Joseph KA; Russo D; Gorroochurn P; Ward M; Horowitz E; El-Tamer MB; Schnabel FR
Cancer; 2004 May; 100(10):2079-83. PubMed ID: 15139048
[TBL] [Abstract][Full Text] [Related]
23. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
24. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact.
Wevers MR; Hahn DE; Verhoef S; Bolhaar MD; Ausems MG; Aaronson NK; Bleiker EM
Patient Educ Couns; 2012 Oct; 89(1):89-95. PubMed ID: 22543000
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic mastectomy and genetic testing: an update.
Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
[TBL] [Abstract][Full Text] [Related]
27. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer after bilateral risk-reducing mastectomy.
Skytte AB; Crüger D; Gerster M; Laenkholm AV; Lang C; Brøndum-Nielsen K; Andersen MK; Sunde L; Kølvraa S; Gerdes AM
Clin Genet; 2011 May; 79(5):431-7. PubMed ID: 21199491
[TBL] [Abstract][Full Text] [Related]
29. [Prophylactic mastectomies and immediate breast reconstruction in patients at very high genetic risk: our experience with 14 cases].
Missana MC; Chompret A
Ann Chir Plast Esthet; 2008 Aug; 53(4):325-33. PubMed ID: 18055089
[TBL] [Abstract][Full Text] [Related]
30. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
[TBL] [Abstract][Full Text] [Related]
31. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
[TBL] [Abstract][Full Text] [Related]
32. Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations.
Howard-McNatt M; Schroll RW; Hurt GJ; Levine EA
Am J Surg; 2011 Sep; 202(3):298-302. PubMed ID: 21871984
[TBL] [Abstract][Full Text] [Related]
33. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
Peterson EA; Milliron KJ; Lewis KE; Goold SD; Merajver SD
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):79-87. PubMed ID: 11815404
[TBL] [Abstract][Full Text] [Related]
34. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic imaging in the clinical management of patients at high risk for breast cancer.
Pastore G; Canadè A; Costantini M; Terribile D; Nardone L; Belli P
Rays; 2002; 27(4):295-8. PubMed ID: 12703481
[TBL] [Abstract][Full Text] [Related]
36. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
37. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
[TBL] [Abstract][Full Text] [Related]
38. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Ardern-Jones A; Kenen R; Eeles R
Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973
[TBL] [Abstract][Full Text] [Related]
39. Management of the BRCA mutation carrier or high-risk patient.
Bordeleau LJ; Lipa JE; Neligan PC
Clin Plast Surg; 2007 Jan; 34(1):15-27; abstract v. PubMed ID: 17307068
[TBL] [Abstract][Full Text] [Related]
40. The role of ovarian ablation in the management of breast cancer.
Wirk B
Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
